Looking beyond short-term turmoil, Syngene is investing for the future
The CRDMO has revamped its leadership and is building capacity as it eyes growth and emerging modalities.
Drug Manufacturers
BMS Texas investment advances pharma’s modular manufacturing agenda
Industry partnership will determine the success of the transition to low-GWP pMDIs
Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing
Turning AI skeptics into AI advocates through high-integrity data
Altaris to acquire Simulations Plus in $375m all-cash deal
University of Edinburgh develops cell therapy for liver disease
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
